By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
There is little governmental oversight of the DRC’s pharmaceutical industry, which is highly fragmented.
For public health facilities, there are multiple parallel pharmaceutical supply systems.The donor supporting the Health zone in which the health facility is situated is largely responsible for the supply system for that facility.
The pharmaceutical supply system for health facilities in the Health zone would probably also change if the donor supporting that zone changed.
Malaria, yellow fever, Ebola, polio, cholera, measles, and tuberculosis continue to affect the DRC.The GDRC provides little financial assistance to the healthcare industry.
The people living in the DRC have a significant demand for pharmaceutical products.Due to their high quality, pharmaceutical products made in the United States are also well-liked by Congolese people
Due to the prevalence of counterfeit pharmaceutical products in the DRC, Congolese eagerly seek authentic American brands.
The Congo Pharmaceutical Market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
In the Democratic Republic of the Congo (DRC), a clinical trial of the antiviral drug tecovirimat, also known as TPOXX, has begun in adults and children with monkeypox.The safety of the drug, its ability to alleviate monkeypox symptoms, and its ability to prevent serious outcomes, including death, will all be evaluated in the trial.
As part of the government-to-government PALM partnership, the DRC’s National Institute for Biomedical Research (INRB) and the U.S. National Institute of Allergy and Infectious Diseases (NIAID) are co-leading the trial.
The World Health Organization (WHO), the Alliance for International Medical Action (ALIMA), the Institute of Tropical Medicine in Antwerp, and the U.S. Centers for Disease Control and Prevention (CDC) are examples of collaborators.
The U.S. Food and Drug Administration has granted approval for the treatment of smallpox to the pharmaceutical company SIGA Technologies, Inc.’s TPOXX.By preventing virus particles from exiting human cells, the medication prevents the virus from spreading throughout the body.
Both the smallpox virus and the monkeypox virus contain a protein that is the target of the drug.
The monkeypox virus has sporadic cases and outbreaks, primarily in the central and west African rainforests.There has been a multi-continent outbreak of monkeypox in places where the disease is not endemic, like Europe and the United States.
The WHO and the US Department of Health and Human Services have recently declared a public health emergency due to the outbreak.
CAISA PHARMA INTERNATIONAL MERKOT PHARMACY SPARK CONGO DEPOT PHARMACEUTIQUE NEXA PHARMA PROMED PHARMA S.A.R.L UNIQUE PHARMA LUBUMBASHI
